Tetrahydroisoquinoline derivatives: A new perspective on monoaminergic dysfunction in children with ADHD?

Behavioral and Brain Functions

Volumn 3, Issue , 2007, Pages

  Roessner, Veit ^a   Walitza, Susanne ^b   Riederer, Franz ^c   Hünnerkopf, Regina ^b   Rothenberger, Aribert ^a   Gerlach, Manfred ^b   Moser, Andreas ^d  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; N METHYL NORSALSOLINOL; N METHYL SALSOLINOL; NORSALSOLINOL; SALSOLINOL; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ANALYTIC METHOD; ARTICLE; ATTENTION DEFICIT DISORDER; CHEMICAL STRUCTURE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; HUMAN; MONOAMINERGIC SYSTEM; PATHOPHYSIOLOGY; PILOT STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINE LEVEL;

EID: 38949204417     PISSN: 17449081     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-9081-3-64     Document Type: Article

References (33)

1. Biederman J Faraone SV Attention-deficit hyperactivity disorder Lancet 2005, 366:9481-237 248 10.1016/S0140-6736(05)66915-2 16023516
2. Grund T Lehmann K Bock N Rothenberger A Teuchert-Noodt G Influence of methylphenidate on brain development - an update of recent animal experiments Behav Brain Funct 2006, 2:2 1363724 16403217 10.1186/ 1744-9081-2-2
3. Sagvolden T Johansen EB Aase H Russell VA A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes Behav Brain Sci 2005, 28(3):397-419; discussion 419-68 10.1017/S0140525X05000075 16209748
4. Madras BK Miller GM Fischman AJ The dopamine transporter and attention-deficit/hyperactivity disorder Biol Psychiatry 2005, 57(11):1397-1409 10.1016/j.biopsych.2004.10.011 15950014
5. Pliszka SR The neuropsychopharmacology of attention-deficit/ hyperactivity disorder Biol Psychiatry 2005, 57(11):1385-1390 10.1016/ j.biopsych.2004.08.026 15950012
6. Shaywitz BA Cohen DJ Bowers MB Jr. CSF monoamine metabolites in children with minimal brain dysfunction: Evidence for alteration of brain dopamine. A preliminary report J Pediatr 1977, 90(1):67-71 10.1016/ S0022-3476(77)80766-X 830896
7. Shetty T Chase TN Central monoamines and hyperkinase of childhood Neurology 1976, 26(10):1000-1002 986582
8. Reimherr FW Wender PH Ebert MH Wood DR Cerebrospinal fluid homovanillic acid and 5-hydroxy-indoleacetic acid in adults with attention deficit disorder, residual type Psychiatry Res 1984, 11(1):71-78 10.1016/ 0165-1781(84)90109-4 6200893
9. Castellanos FX Elia J Kruesi MJ Marsh WL Gulotta CS Potter WZ Ritchie GF Hamburger SD Rapoport JL Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/ hyperactivity disorder Neuropsychopharmacology 1996, 14(2):125-137 10.1016/0893-133X(95)00077-Q 8822535
10. Storch A Hofer A Kruger R Schulz JB Winkler J Gerlach M New developments in diagnosis and treatment of Parkinson's disease - from basic science to clinical applications J Neurol 2004, 251(Suppl 6):VI/33 8
11. Mravec B Salsolinol, a derivate of dopamine, is a possible modulator of catecholaminergic transmission: A review of recent developments Physiol Res 2005 16238467
12. Meisenberg G Simmons WH Collins MA Effects of catecholamine-related mammalian alkaloids on spontaneous and vasopressin-induced behavior in mice Pharmacol Biochem Behav 1984, 20(3):355-360 10.1016/ 0091-3057(84)90270-3 6324242
13. Antkiewicz-Michaluk L Michaluk J Romanska I Papla I Vetulani J Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol J Neural Transm 2000, 107(8-9):1009-1019 10.1007/ s007020070049 11041279
14. Costall B Naylor RJ Pinder RM Hyperactivity induced by tetrahydroisoquinoline derivatives injected into the nucleus accumbens Eur J Pharmacol 1976, 39(1):153-160 10.1016/0014-2999(76)90123-0 134899
15. Niwa T Takeda N Yoshizumi H Tatematsu A Yoshida M Dostert P Naoi M Nagatsu T Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonian and normal human brains Biochem Biophys Res Commun 1991, 177(2):603-609 10.1016/0006-291X(91)91831-V 2049084
16. Moser A Scholz J Nobbe F Vieregge P Bohme V Bamberg H Presence of N-methyl-norsalsolinol in the CSF: Correlations with dopamine metabolites of patients with Parkinson's disease J Neurol Sci 1995, 131(2):183-189 10.1016/0022-510X(95)00110-N 7595645
17. Scholz J Klingemann I Moser A Increased systemic levels of norsalsolinol derivatives are induced by levodopa treatment and do not represent biological markers of Parkinson's disease J Neurol Neurosurg Psychiatry 2004, 75(4):634-636 10.1136/jnnp.2003.010769 15026514
18. Musshoff F Schmidt P Dettmeyer R Priemer F Wittig H Madea B A systematic regional study of dopamine and dopamine-derived salsolinol and norsalsolinol levels in human brain areas Forensic Sci Int 1999, 105(1):1-11 10.1016/S0379-0738(99)00110-3 10605071
19. Naoi M Maruyama W Dostert P Kohda K Kaiya T A novel enzyme enantio-selectively synthesizes (R)salsolinol, a precursor of a dopaminergic neurotoxin, N-methyl(R)salsolinol Neurosci Lett 1996, 212(3):183-186 10.1016/0304-3940(96)12807-X 8843103
20. Naoi M Maruyama W Matsubara K Hashizume Y A neutral N-methyltransferase activity in the striatum determines the level of an endogenous MPP+-like neurotoxin, 1,2-dimethyl-6,7-dihydroxyisoquinolinium ion, in the substantia nigra of human brains Neurosci Lett 1997, 235(1-2):81-84 10.1016/S0304-3940(97)00723-4 9389601
21. Riggin RM McCarthy MJ Kissinger PT Identification of Salsolinol as a Major Dopamine Metabolite in Banana Journal of Agricultural and Food Chemistry 1976, 24(1):189-191 10.1021/jf60203a027
22. Strolin Benedetti M Dostert P Carminati P Influence of food intake on the enantiomeric composition of urinary salsolinol in man J Neural Transm Gen Sect 1989, 78(1):43-51 10.1007/BF01247112 2754429
23. Schnoll R Burshteyn D Cea-Aravena J Nutrition in the treatment of attention-deficit hyperactivity disorder: A neglected but important aspect Appl Psychophysiol Biofeedback 2003, 28(1):63-75 10.1023/ A:1022321017467 12737097
24. Marcason W Can dietary intervention play a part in the treatment of attention deficit and hyperactivity disorder? J Am Diet Assoc 2005, 105(7):1161-1162 10.1016/j.jada.2005.05.260 15983541
25. Solanto MV Dopamine dysfunction in AD/HD: Integrating clinical and basic neuroscience research Behav Brain Res 2002, 130(1-2):65-71 10.1016/ S0166-4328(01)00431-4 11864719
26. American-Psychiatric-Association Diagnostic and statistical manual of mental disorders DSM-IV-TR (Text Revision) Washington, American Psychiatric Association 4th 2000
27. Moser A Scholz J Bamberg H Bohme V The effect of N-methyl-norsalsolinol on monoamine oxidase of the rat caudate nucleus in vitro Neurochem Int 1996, 28(1):109-112 10.1016/0197-0186(95)00048-D 8746770
28. Moser A Pharmacology of endogenous neurotoxins: A handbook Boston, Birkhäuser 1998
29. Feuerstein TJ Rossner R Schumacher M How to express an effect mean as percentage of a control mean? J Pharmacol Toxicol Methods 1997, 37(4):187-190 10.1016/S1056-8719(97)00017-8 9279773
30. Moser A Siebecker F Vieregge P Jaskowski P Kompf D Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease J Neural Transm 1996, 103(4):421-432 10.1007/BF01276418 9617786
31. Thumen A Behnecke A Qadri F Bauml E Behnecke CA Moser A N-methyl-norsalsolinol, a putative dopaminergic neurotoxin, passes through the blood-brain barrier in vivo Neuroreport 2002, 13(1):25-28 10.1097/00001756-200201210-00010 11924888
32. Hirtz DG Fitzsimmons LG Regulatory and ethical issues in the conduct of clinical research involving children Curr Opin Pediatr 2002, 14(6):669-675 10.1097/00008480-200212000-00003 12436032
33. Arnsten AF Stimulants: Therapeutic actions in ADHD Neuropsychopharmacology 2006, 31(11):2376-2383 10.1038/sj.npp.1301164 16855530